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Abstract
Background: Brain-derived neurotrophic factor (BDNF) is a small secreted protein that has
important roles in the developing and adult nervous system. Altered expression or changes in the
regulation of the BDNF gene have been implicated in a variety of human nervous system disorders.
Although regulation of the rodent BDNF gene has been extensively investigated, in vivo studies
regarding the human BDNF gene are largely limited to postmortem analysis. Bacterial artificial
chromosome (BAC) transgenic mice harboring the human BDNF gene and its regulatory flanking
sequences constitute a useful tool for studying human BDNF gene regulation and for identification
of therapeutic compounds modulating BDNF expression.
Results: In this study we have generated and analyzed BAC transgenic mice carrying 168 kb of the
human BDNF locus modified such that BDNF coding sequence was replaced with the sequence of
a fusion protein consisting of N-terminal BDNF and the enhanced green fluorescent protein
(EGFP). The human BDNF-BAC construct containing all BDNF 5' exons preceded by different
promoters recapitulated the expression of endogenous BDNF mRNA in the brain and several non-
neural tissues of transgenic mice. All different 5' exon-specific BDNF-EGFP alternative transcripts
were expressed from the transgenic human BDNF-BAC construct, resembling the expression of
endogenous BDNF. Furthermore, BDNF-EGFP mRNA was induced upon treatment with kainic
acid in a promotor-specific manner, similarly to that of the endogenous mouse BDNF mRNA.
Conclusion: Genomic region covering 67 kb of human BDNF gene, 84 kb of upstream and 17 kb
of downstream sequences is sufficient to drive tissue-specific and kainic acid-induced expression of
the reporter gene in transgenic mice. The pattern of expression of the transgene is highly similar
to BDNF gene expression in mouse and human. This is the first study to show that human BDNF
gene is regulated by neural activity.
Background
Brain-derived neurotrophic factor (BDNF) [1], a member
of the neurotrophin family, promotes survival and differ-
entiation of several neuronal populations during mam-
malian development [2,3]. In the adult central nervous
system, BDNF acts as a regulator of activity-dependent
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neurotransmission and plasticity [4] and promotes sur-
vival of newborn hippocampal neurons [5]. BDNF has
widespread expression in the developing and adult mam-
malian nervous system, its mRNA and protein levels rising
dramatically in postnatal development [6-10]. In the
adult, BDNF is also expressed in a number of non-neural
tissues, with the highest levels of BDNF mRNA detected in
thymus, heart and lung [11,12].
BDNF gene has a complex structure with multiple
untranslated 5' exons alternatively spliced to one protein-
coding 3' exon. The rat BDNF gene structure initially
described to contain five exons [13] has been recently
updated with a number of newly discovered exons for
rodent [14,15] and human [16,17] BDNF. Untranslated 5'
exons are linked with differentially regulated promoters
directing tissue-specific expression of BDNF [13-17]. Fur-
thermore, recently discovered BDNF antisense transcripts
in human may exert additional control over BDNF tran-
scription [16,17]. BDNF is a neural activity-dependent
gene in rodents: various physiological stimuli induce its
expression in neurons through excitatory neurotransmis-
sion-triggered calcium influx [18,19]. However, no data is
available about activity-dependent transcription of the
human BDNF gene in neurons, except one report showing
that dopamine signaling increases the levels of BDNF
exon IV transcripts in neuronally differentiated human
embryonic teratocarcinoma NT2 cells [20].
Alterations in BDNF function have been associated with a
variety of disorders of the nervous system [2]. As therapies
modulating neurotrophic activity are being actively
sought [21], it is of great importance to create model sys-
tems for studying the regulation of BDNF gene. BAC trans-
genic mice have proven useful in studying gene regulation
as a) BAC clones are often long enough to contain all nec-
essary DNA elements to recapitulate the expression pat-
terns of endogenous genes independent of host genomic
sequences flanking the transgene integration site and b)
they can be easily modified with homologous recombina-
tion in E. coli, e.g. to introduce reporter genes under the
control of promoters of interest [22]. BAC transgenes with
EGFP reporter gene have been used for characterization of
expression and regulatory regions of several neural genes
[23-25]. Transgenic mice have been generated previously
to study BDNF gene regulation in vivo [26,27]. Mouse
lines carrying rat BDNF sequences of 10 kb range recapit-
ulated BDNF expression only partially, suggesting that cis-
acting regulatory elements necessary for accurate control
of BDNF expression are located further away [26].
Recently, YAC-BDNF transgenic mice carrying 145 kb of
human BDNF locus with BDNF coding sequence substi-
tuted for the EGFP reporter gene have been reported [27].
In this study we have generated BAC transgenic mice car-
rying human BDNF-EGFP fusion (hBDNF-EGFP) reporter
gene under the control of 168 kb of human BDNF
genomic sequences. C-terminal addition of EGFP to
BDNF protein has been shown not to affect BDNF cellular
localization, secretion and activation of its receptor TrkB
in cultured neurons [28-30]. Therefore, to enable studying
subcellular localization of the hBDNF-EGFP fusion pro-
tein in vivo, we specifically produced this fusion reporter
gene construct. The aims of the study were to investigate
a) expression of hBDNF-EGFP mRNA and protein in the
brain and non-neural tissues and b) activity-dependent
regulation of the hBDNF-EGFP transgene in the brain of
the BAC transgenic mice.
Results
Generation of transgenic mice with 169 kb hBDNF-EGFP-
BAC
A 168 kb BAC clone extending 84 kb upstream and 17 kb
downstream of human BDNF gene was used to generate
human BDNF-EGFP reporter transgenic mice (see Materials
and Methods and Figure 1A–C). Briefly, EGFP reporter gene
was inserted in-frame with BDNF coding region replacing
the BDNF stop codon (Figure 1C). Resulting hBDNF-EGFP
fusion protein was expected to mimic subcellular localiza-
tion of endogenous BDNF, allowing fine resolution of trans-
gene expression. hBDNF-EGFP-BAC construct was tested for
integrity using PCR and restriction analysis (data not
shown). Transgenic mice were generated by pronuclear
injection, yielding four transgenic founders (A4, E1, E4 and
C3). All founders contained one to two transgene copies as
estimated by slot-blot hybridization (Figure 1D). PCR anal-
ysis of C3 genomic DNA and sequencing of the PCR prod-
ucts revealed tandem integration of two transgene copies
and confirmed the intactness of 5' and 3' end sequences of
the integrated transgene (Figure 1E). Offspring was obtained
from three founders and bred for several generations to gen-
erate transgenic mouse lines E1, E4 and C3.
Expression of hBDNF-EGFP in transgenic mouse tissues
From three transgenic founder lines, C3 line showed pat-
tern of expression of hBDNF-EGFP mRNAs that was
highly similar to the expression of mouse endogenous
BDNF (mBDNF) mRNA (Figure 2A). RT-PCR analysis
revealed relatively high transgene expression in all brain
regions of C3 mice, including cerebral cortex, hippocam-
pus, striatum, thalamus, hypothalamus, midbrain, pons,
medulla and cerebellum. In non-neural tissues, high lev-
els of transgene mRNA were detected in testis, moderate
levels in thymus and lung and low levels in skeletal mus-
cle. BDNF mRNA is endogenously expressed in all these
tissues both in mouse and human [14,16]; (Figure 2A).
However, dissimilarly from mouse endogenous BDNF
mRNA, hBDNF-EGFP mRNA was not detected in heart
and kidney, where relatively high levels of mBDNF mRNA
were detected. Low expression of hBDNF-EGFP transgene
in the mouse kidney correlates with the finding that
BDNF is expressed at low levels in human kidney [8,16].BMC Neuroscience 2009, 10:68 http://www.biomedcentral.com/1471-2202/10/68
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In E1 mice, transgene expression recapitulated that of the
endogenous BDNF mRNA in thymus, lung, kidney and
testis, but not in other non-neural tissues that express
BDNF. In the adult brain of E1 mice, transgene mRNA
expression was detected in midbrain, cerebellum, pons
and medulla at levels that were lower than in the respec-
tive brain regions of C3 mice. In E4 line, hBDNF-EGFP
mRNA was detected only in testis and thymus (Figure 2A).
Expression of transgenic hBDNF-EGFP mRNA was further
examined in different brain regions of C3 mice since this
line largely recapitulated endogenous BDNF expression
and expressed the transgene at the highest levels. Quanti-
fication of hBDNF-EGFP transcripts in C3 hippocampus
and cortex using ribonuclease protection assay (RPA)
revealed that transgene mRNA levels were about tenfold
lower than endogenous mBDNF mRNA levels (Figure
2B). Analysis of transcription from the alternative human
BDNF promoters in C3 mice confirmed the expression of
all transcripts with different 5' exons described to date
(exons I-IXe) both in hippocampus (Figure 2C) and cere-
bral cortex (data not shown).
In situ hybridization of C3 mice adult brain sections
revealed hBDNF-EGFP mRNA expression in the hippoc-
ampus, particularly in the pyramidal neurons of CA1 and
CA3 regions and in the polymorphic neurons in the hilus
of the dentate gyrus, and also in several cortical areas,
including neurons of frontal, sensorimotor and piriform
cortex (Figure 3, 4). Endogenous mBDNF mRNA was
detected in all brain areas where hBDNF-EGFP mRNA
labeling was observed. However, hBDNF-EGFP labeling
was absent or below the detection limit of our in situ
hybridization assay in several areas expressing mBDNF
mRNA, e.g. claustrum, amygdala, thalamic, hypothalamic
and pontine nuclei. Furthermore, in situ hybridization
Schematic drawings of rodent and human BDNF genes and the BAC transgenic construct used in this study Figure 1
Schematic drawings of rodent and human BDNF genes and the BAC transgenic construct used in this study. 
Rodent (A) and human (B) BDNF gene structures. Rodent BDNF gene consists of a number of 5' exons (I-VIII) spliced 
together with a common protein-coding sequence in exon IX (transcriptional start sites are indicated with arrows). BDNF 
transcription can also start from exon IX introducing a unique 5' UTR sequence. Hatched lines indicate sites of alternative 
splicing. Although the human BDNF gene has a similar structure and splicing pattern, it has additional exons Vh and VIIIh, 
longer and more complexly spliced 5'UTR of exon IX. Furthermore, human BDNF exons VIII and VIIIh are not used as 5'exons, 
but are always spliced with exon V. For detailed description see [14,16]. (C) Schematic drawing of the modified BAC construct 
used in this study containing the human BDNF locus. EGFP reporter gene was inserted in-frame with the BDNF coding region 
before the BDNF stop codon creating a fused BDNF-EGFP open reading frame within 168 kb of human BDNF locus. Arrows 
P1-3 indicate PCR primers used for analysis of transgene integration. (D) Slot-blot hybridization analysis of transgene copy 
number in hBDNF-EGFP transgenic founder mice (A4, C3, E1 and E4). BAC standard contains hBDNF-EGFP-BAC DNA in 
amounts equivalent to 1–3 copies of transgene in the blotted genomic DNA. WT- wild type mouse DNA. (E) PCR analysis of 
genomic DNA from transgenic mouse line C3 with primers detecting tandem integration of hBDNF-EGFP-BAC constructs. 
WT – wild type mouse DNA as a negative control; (+) – circular hBDNF-EGFP-BAC DNA as a positive control; (-) – PCR 
without DNA as a negative control.
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showed differential expression of hBDNF and mBDNF in
cortical and hippocampal subfields. While mBDNF
mRNA was expressed at high levels throughout the cere-
bral cortex, hBDNF-EGFP labeling was more prominent in
the frontal cortex and in the sensorimotor area extending
along the longitudinal fissure (Figure 3C, D and Figure
4K–N). In the hippocampus, hBDNF-EGFP labeling was
observed over the CA1 and hilar subfields and part of the
CA3 subfield (CA3b in Figure 3G, H and Figure 4C, D),
mimicking the pattern of expression of endogenous
mBDNF mRNA. On the other hand, hBDNF-EGFP mRNA
was expressed at considerably lower levels in the part of
CA3 subfield that showed high levels of mBDNF mRNA
expression (CA3a in Figure 3G, H and Figure 4E, F). In
addition, no hBDNF-EGFP labeling was detected in the
granule neurons of dentate gyrus where endogenous
mBDNF mRNA was highly expressed (Figure 3G, H and
Figure 4I, J).
Since the BDNF gene in the transgenic construct was of
human origin, we also analyzed the expression of BDNF
in the human hippocampus using in situ hybridization. In
agreement with earlier findings [31,32], our results
showed that the highest levels of hBDNF mRNA were
hBDNF-EGFP mRNA expression in tissues of three trans- genic mouse lines Figure 2
hBDNF-EGFP mRNA expression in tissues of three 
transgenic mouse lines. (A) RT-PCR analysis of hBDNF-
EGFP mRNA expression in tissues of three transgenic BAC 
mouse lines – C3, E1, E4. mBDNF – mouse BDNF; hBDNF – 
human BDNF in human tissues; HPRT – reference gene 
hypoxanthine phosphoribosyltransferase. Cx – cortex; Hc – 
hippocampus; St – striatum; Th – thalamus; Mb – midbrain; 
PM – pons/medulla; Cb – cerebellum; Ty – thymus; He – 
heart; Lu – lung; Li – liver; Ki – kidney; SM – skeletal muscle; 
Sp – spleen; Te – testis. (B) Analysis of hBDNF-EGFP mRNA 
expression levels in C3 mouse brain by RNase protection 
assay. hBDNF-EGFP probe was used to determine both 
transgenic and endogenous BDNF mRNA levels as protein 
coding sequences of mouse and human BDNF share a high 
degree of similarity. P – probe without RNase; tRNA – yeast 
tRNA; HC – hippocampus; CX – cortex. On the right, black 
boxes denote vector-derived sequences, white boxes BDNF 
and gray boxes EGFP sequences. (C) Expression of alterna-
tive hBDNF-EGFP transcripts in C3 mouse hippocampus 
(HC), analyzed by RT-PCR. PCR primers used were specific 
for human BDNF transcripts as shown by control reactions 
with human (hHC) and mouse (mHC) hippocampal cDNA. 
eIX – transcript containing 5'-extended exon IX.
Overlapping patterns of BAC-driven hBDNF-EGFP and  mBDNF mRNA expression in C3 mouse brain Figure 3
Overlapping patterns of BAC-driven hBDNF-EGFP 
and mBDNF mRNA expression in C3 mouse brain. In 
situ hybridization analysis, photoemulsion autoradiographs of 
16 μm sagittal (A,B) and coronal (C-H) sections. (C) and 
(D) are sections taken at striatal level; (E) and (F) are sec-
tions taken at posterior hippocampal levels; (G) and (H) 
show enlarged hippocampal area (scale bar: 0,5 mm). FC – 
frontal cortex;SM – sensorimotor cortex; HC – hippocam-
pus; Pn – pontine nuclei; Hth – hypothalamus; Cg – cingulate 
cortex; Pir – piriform cortex; Cl – claustrum; Str – striatum; 
CA1, CA3 – hippocampal subfields; DG – dentate gyrus of hip-
pocampus; Hi – hilar area of dentate gyrus; Th – thalamus; 
Amy – amygdala.BMC Neuroscience 2009, 10:68 http://www.biomedcentral.com/1471-2202/10/68
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present in the granule cells of dentate gyrus, whereas other
hippocampal regions showed relatively weaker expression
(Figure 5). However, strong hBDNF labeling was detected
over majority of CA3 and CA1 neurons using high magni-
fication (Figure 5B, C), indicating that these areas show
much weaker signal in the dark-field image partly because
of the scarcity of neuronal cell bodies in the CA1 and CA3
subfields of the human hippocampus.
Next we examined expression of hBDNF-EGFP fusion pro-
tein across tissues in C3 mice. No EGFP fluorescence was
observed in brain sections or cultured primary embryonic
(E18) hippocampal neurons. In addition, hBDNF-EGFP
protein was not detected in the hippocampus, cortex and
testis by Western blot analysis with anti-EGFP or anti-
BDNF antibodies (data not shown). hBDNF-EGFP open
reading frame in C3 genomic DNA was analyzed for pos-
sible mutations by sequencing and was found to be intact.
Together with mRNA expression data these results suggest
that hBDNF-EGFP protein was either not translated in the
brain and testis of C3 mice or was expressed at levels
below the detection limits of our methods.
Kainic acid induces hBDNF-EGFP mRNA expression in 
transgenic mouse brain
Kainic acid (KA), agonist of the KA subtype ionotropic
glutamate receptor, has been shown to induce BDNF
mRNA levels in adult rodent hippocampus and cerebral
cortex [13,19,33,34]. KA induction of transgenic hBDNF-
EGFP transcripts in the hippocampus and cerebral cortex
of C3 mice largely followed the induction pattern of
endogenous mBDNF transcripts (Figure 6A). KA markedly
Cellular expression of hBDNF-EGFP mRNA in adult C3 mouse brain Figure 4
Cellular expression of hBDNF-EGFP mRNA in adult C3 mouse brain. In situ hybridization analysis, shown are bright-
field autoradiographs of emulsion-dipped sections. Hybridization probes are indicated above the columns. Filled arrowhead 
indicates a neuron with strong labeling, empty arrowhead indicates a neuron with weak or absent labeling and double arrow-
heads indicate a glial cell showing no labeling. CA1, CA3 – hippocampal subfields; DG – dentate gyrus of hippocampus; Hi – hilar 
area of dentate gyrus; FC – frontal cortex; SM – sensorimotor cortex; Pir – piriform cortex. Scale bar: 20 μm.
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upregulated both endogenous mouse and transgenic
hBDNF-EGFP transcripts containing exons I, IV and 5'-
extended exon IX (eIX) in the hippocampus and cortex.
hBDNF-EGFP and mBDNF mRNAs containing other 5'
exons were induced to a lesser extent. Of note, recently
described human-specific exon Vh-containing transcripts
were not induced by KA in transgenic mice in the context
of 169 kb hBDNF-EGFP BAC construct (Figure 6A).
Levels of BDNF transcripts showing the most robust
induction by kainic acid were analyzed further using
quantitative real-time RT-PCR analysis (Figure 6B). Trans-
genic hBDNF-EGFP exon I, exon IV and 5'-extended exon
Expression of BDNF mRNA in the human hippocampus Figure 5
Expression of BDNF mRNA in the human hippocam-
pus. (A) In situ hybridization autoradiograph of a 16 μm 
coronal section.DG – granular layer of dentate gyrus; Hi – 
hilar area of dentate gyrus; Sub – subiculum; CA1, CA3 – hip-
pocampal subfields. (B-E) High magnification bright-field pho-
tomicrographs of hematoxylin-counterstained neurons in 
subfields CA1 (B) and CA3 (C), the hilus (D) and granular 
layer of dentate gyrus (E). Filled arrowhead indicates a neu-
ron with strong labeling, empty arrowhead indicates a neu-
ron with weak or absent labeling and double arrowheads 
indicate a glial cell showing no labeling.
Kainic acid (30 mg/kg) induces transgenic hBDNF-EGFP  mRNA expression in brains of C3 line transgenic mice Figure 6
Kainic acid (30 mg/kg) induces transgenic hBDNF-
EGFP mRNA expression in brains of C3 line trans-
genic mice. (A) Induction of alternatively spliced hBDNF-
EGFP transcripts in C3 mouse hippocampus (HC) and cere-
bral cortex (CTX), analyzed with RT-PCR. mBDNF – mouse 
transcripts; ND – not determined; KA – kainic acid treated 
mice; CTR – control mice. Three BDNF-II bands correspond 
to alternatively spliced transcripts. (B) Quantitative real-time 
RT-PCR analysis of selected BDNF transcripts, normalized to 
HPRT1 levels and expressed as fold difference relative to 
mRNA levels in untreated mice. (C) In situ hybridization 
autoradiographs of C3 mouse coronal brain sections. Pir – 
piriform cortex; CA1, CA3 – hippocampal subfields; DG – den-
tate gyrus of hippocampus; Hi – hilar area of dentate gyrus; 
Th – thalamus; Hth – hypothalamus; Amy – amygdala.
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IX transcripts, and total hBDNF-EGFP mRNA were
potently induced in both hippocampus and cortex follow-
ing 3 hours of kainate treatment, similarly to respective
endogenous mBDNF mRNAs. Exon VI-containing
hBDNF-EGFP and endogenous mBDNF transcripts
showed no induction, which is consistent with previous
findings [13,14,33].
In situ hybidization analysis showed marked induction of
transgenic hBDNF-EGFP mRNA by KA in the pyramidal
neurons of CA1-CA3 layers, in the hilar region of hippoc-
ampus and also in the layers II – VI of cerebral cortex (Fig-
ure 6C). Importantly, kainic acid induced transgene
expression also in the granular layer of dentate gyrus of
hippocampus, whereas control animals did not show any
detectable expression in this area. Endogenous mBDNF
was induced in the same neuronal populations, suggest-
ing that the 169 kb hBDNF-EGFP BAC construct contains
all the regulatory elements that mediate kainic acid induc-
tion. We also examined expression of the hBDNF-EGFP
protein in the brains of kainic acid treated C3 mice by
direct EGFP fluorescence and Western blot analysis but no
fusion protein was detected (data not shown).
Discussion
In this study, BAC transgenic mice carrying 168 kb of the
human BDNF locus and encoding human BDNF-EGFP
fusion protein were generated and analyzed. Out of three
analyzed founder lines, one line (C3) largely recapitulated
human BDNF mRNA expression in the brain, thymus,
lung, skeletal muscle and testis. Founder line E1 mim-
icked human BDNF mRNA expression in some brain
regions, and also in thymus, lung and kidney. Founder
line E4 expressed transgene only in the thymus and testis.
These results showed that although all three founder lines
expressed hBDNF-EGFP mRNA at different levels, the 169
kb BAC construct, carrying 67 kb of human BDNF gene,
84 kb of 5' and 17 kb of 3' sequences, contains regulatory
elements necessary for hBDNF mRNA expression in many
brain regions and non-neural tissues. However, integra-
tion site-dependent expression of transgene in different
founder lines suggests that the BAC construct may not
contain necessary insulator elements to protect it from the
influence of genomic regions flanking the transgene inte-
gration site. It has been shown for many genes that insu-
lators can functionally isolate neighboring genes and
block their interactions [35].
In several non-neural tissues, the 169 kb hBDNF-EGFP
BAC recapitulated endogenous expression of both mouse
and human BDNF. Transgenic mRNA was expressed in
the thymus and testis in three mouse lines, expression in
the lung was seen in two lines and only one line expressed
hBDNF-EGFP in the kidney and skeletal muscle. All these
tissues have been shown to express BDNF both in mouse
and human [7,14,16]. Of note, all three founder lines
expressed relatively high levels of hBDNF-EGFP in adult
testis, in contrast to the very low expression levels of
endogenous mBDNF in the testis. This transgene expres-
sion pattern can be explained by human origin of the
BDNF gene as relatively high levels of BDNF mRNA, com-
parable to the levels in the brain, have been detected in
the human testis [16]. In the adult human testis, expres-
sion of BDNF and its receptor TrkB has been reported in
Leydig, Sertoli and germ cells [36], while in the adult
mouse testis, BDNF expression has been detected in Ser-
toli cells and expression of its receptor TrkB in germ cells
[37]. These findings indicate differences in BDNF expres-
sion between human and mouse and are further sup-
ported by the present study. On the other hand, none of
the founder lines expressed hBDNF mRNA in the heart, a
tissue with high levels of BDNF expression both in human
and rodents [8,11,12,14]. This suggests that distinct heart-
specific regulatory elements are located outside of the
genomic DNA fragment that was included in the BAC con-
struct.
Detailed analysis of hBDNF-EGFP expression in the C3
mouse brain by in situ hybridization showed that the
transgene mimicked mBDNF expression in many neuron
populations, including neurons of the CA1-CA3 and hilar
regions of the hippocampus and the cerebral cortex. How-
ever, hBDNF-EGFP failed to recapitulate endogenous
BDNF expression in several neuron populations, includ-
ing the granule cells of dentate gyrus of hippocampus
where BDNF mRNA is expressed both in human and
rodents. hBDNF-EGFP expression was detected in all ana-
lyzed brain regions by RT-PCR, but not by in situ hybridi-
zation, indicating that transgene mRNA levels in several
brain structures were below the detection limit of our in
situ hybridization analysis.
BDNF transcription is regulated by neuronal activity
through calcium-mediated pathways [18,38]. Systemic
treatment of rodents with kainic acid (KA) has been used
to model activity-dependent induction of BDNF mRNA in
the nervous system [13,19,33,34]. Here we show that KA
differentially induced alternative hBDNF-EGFP tran-
scripts in the cortex and hippocampus (for comparison
with mouse and rat see Table 1). Pronounced induction of
transgenic hBDNF-EGFP transcripts containing exons I,
IV, and 5'-extended exon IX (eIX), moderate induction of
transcripts containing exons II, III and absence of induc-
tion of transcripts containing exon VI is consistent with
the induction pattern of respective BDNF mRNAs in
mouse and rat [13,14,33]. To our knowledge, this is the
first time to report neural activity-dependent regulation of
the human BDNF gene in vivo. Real-time PCR showed that
total transgenic mRNA, as well as transcripts containing
exons I, IV and 5'-extended exon IX were induced to aBMC Neuroscience 2009, 10:68 http://www.biomedcentral.com/1471-2202/10/68
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lesser extent than the respective endogenous mBDNF
mRNAs. This is consistent with earlier results reported for
shorter rat BDNF transgenes [26] and could be caused by
increased stability of transgenic BDNF-reporter mRNAs as
compared to the mouse endogenous BDNF mRNAs. Alter-
natively, the absence of important regulatory elements in
the transgenic construct may underlie the reduced induc-
tion of the transgene by kainic acid. In situ hybridization
analysis of KA-treated C3 mouse brains showed induction
of hBDNF-EGFP mRNAs in several neuronal populations
where endogenous BDNF mRNA levels were also
increased. These results show that, similarly to rodent
BDNF, expression of the human BDNF gene is induced by
neural activity and that regulatory elements mediating the
induction are included in the 168 kb of the human BDNF
locus contained in the BAC transgene. Several regulatory
elements located in the rat BDNF proximal promoter IV
and the transcription factors mediating activity-depend-
ent activation of this promoter have previously been char-
acterized [39]. Among these elements, CRE (cAMP-
response element) was found to be the most important
for Ca2+-mediated activation of rodent BDNF promoter IV
[40-42]. However, the respective regulatory elements and
transcription factors responsible for the activity-depend-
ent regulation of the human BDNF gene have not been
characterized. Transgenic mice described here can be used
to study the regulation of human BDNF gene in vivo using
a variety of methods successfully applied in the studies of
rodent BDNF [39].
Previously, transgenic mice carrying shorter fragments of
the BDNF locus have been generated and characterized
[26,27]. Mice expressing the CAT reporter gene under the
control of 9 kb of rat BDNF genomic sequences covering
promoters I-III or promoters IV-VI showed relatively high
CAT activity in most tissues and brain regions expressing
endogenous BDNF mRNA. In situ hybridization analysis
showed that these constructs carrying either BDNF pro-
moters I-III or IV-VI were able to drive CAT mRNA expres-
sion in adult rat brain in a pattern largely overlapping
with mouse BDNF mRNA expression. Nevertheless, reca-
pitulation of endogenous BDNF expression had a number
of shortcomings in these transgenes: both constructs were
not expressed or were expressed at low levels in the den-
tate granule cells and granule cells of cerebellum; BDNF
IV-VI did not mimic BDNF expression in the heart; both
constructs displayed relatively high reporter activity in the
striatum where rat BDNF is virtually not expressed [43]. It
was assumed that these transgenic constructs lacked
important regulatory elements, which could be present in
a much longer gene fragment than the BAC clone used
here. Although BAC transgenic mouse lines generated in
this study showed improved recapitulation of expression
as compared to that of the BDNF-CAT transgenic mice
[26], we could not detect transgene expression in several
tissues and neuron populations that express endogenous
BDNF mRNA.
A recent study reported generation of human BDNF-EGFP
transgenic mice using a 145 kb YAC clone including 45 kb
of 5' and 33 kb of 3' flanking sequences of hBDNF gene
with the protein coding sequence partially replaced with
EGFP reporter gene [27]. Three out of five transgenic
founder lines obtained in that study expressed transgenic
mRNA in the brain and only one of these showed expres-
sion of transgenic hBDNF transcripts containing exons IV
and VI in the heart. Out of three lines analyzed, EGFP flu-
orescence was detected in the brain of only one line, spe-
cifically in the claustrum, intermediate layer of parietal
cortex, pyramidal cell layer of CA3 hippocampal subfield
and a population of neurons in the granule cell layer of
the dentate gyrus. However, EGFP fluorescence was not
detected in other cortical neuron populations and in the
CA1 region of hippocampus where rodent and also
human BDNF mRNA are expressed [27]. Differences in
the tissue- and neuron-specific expression of transgenic
hBDNF-EGFP mRNA and protein between the study by
Guillemot et al. [27] and this study can be explained with
different lengths of the BDNF gene-flanking genomic
regions in the transgenic constructs used: the hBDNF-BAC
Table 1: Regulation of human, mouse and rat BDNF exon-
specific mRNAs by kainic acid in the hippocampus and cerebral 
cortex.
human1 mouse2 rat3
exon HC CTX HC CTX HC
I * * * ** * * ** *
II * * * * *
III *- * * * -
IV ** ** ** ** **
V * * * ** **
Vh - - X X X
VI - - - - -
V I I N D N DN D N D* *
VIII X X ND ND *
e I X * * * ** * * ** *
- no induction; * weak induction; ** strong induction; ND – not 
determined; X – transcript containing this exon as the 5' exon does 
not exist in this organism; 1,2 based on data from the present study; 3 
based on data from [14]; HC – hippocampus; CTX – cerebral cortex.BMC Neuroscience 2009, 10:68 http://www.biomedcentral.com/1471-2202/10/68
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Table 2: PCR primers used in this study
Primer/application Sequence
BAC modification
hBDNFcod_rpsL_neo_s 5' GGATAGACACTTCTTGTGTATGTACATTGACCATTAAA 
AGGGGAAGATAGGGCCTGGTGATGATGGCGGGATCG 3'
hBDNF_rpsL_neo_as 5'AATAGATAATTTTTGTCTCAATATAATCTAATCTATACAACATAAATCCATCAGAAGAACTCGTCAA
GAAGG 3'
hBDNFcod_linker_EGFP_s 5' TAAGGATAGACACTTCTTGTGTATGTACATTGACCAT 
TAAAAGGGGAAGACGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTG 3'
hBDNF_EGFP_as 5' AATAGATAATTTTTGTCTCAATATAATCTAATCTATAC 
AACATAAATCCATTACTTGTACAGCTCGTCCATGCCGA 3'
genotyping/slot-blot hybridization/expression analysis
hBDNF_s GTACGTGCGGGCCCTTACCATGGATAGC
EGFP_as TGGTGCAGATGAACTTCAGGGTCAGC
expression analysis
mBDNF_s GTATGTTCGGGCCCTTACTATGGATAGC
mBDNF_as AAGTTGTGCGCAAATGACTGTTTC
HPRT1_s CTTTGCTGACCTGCTGGATTAC
HPRT1_as GTCCTTTTCACCAGCAAGCTTG
hBDNF_I_s GATGCCAGTTGCTTTGTCTTCTGTAG
hBDNF_II_s GGGCGATAGGAGTCCATTCAGCACC
hBDNF_III_s AGTTTCGGGCGCTGGCTTAGAG
hBDNF_IV_s GCTGCAGAACAGAAGGAGTACA
hBDNF_V_s TCGCGTTCGCAAGCTCCGTAGTG
hBDNF_Vh_s GGCTGGAACACCCCTCGAA
hBDNF_VI_s GGCTTTAATGAGACACCCACCGC
hBDNF_VII_s GAACTGAAAGGGTCTGCGACACTCT
hBDNF_IXb_s GCTGCTAAAGTGGGAAGAAGG
hBDNF_IX_as1 GTCCTCATCCAACAGCTCTTCTATC
hBDNF_IX_as2 (with VII_s) GAAGTGTACAAGTCCGCGTCCTTA
expression analyis (qPCR)
EGFPq_s CAGAAGAACGGCATCAAGGTGBMC Neuroscience 2009, 10:68 http://www.biomedcentral.com/1471-2202/10/68
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EGFPq_as TGGGTGCTCAGGTAGTGGTTG
hBDNFq_I_s CAGCATCTGTTGGGGAGACGAGA
hBDNFq_IV_s GAAGTCTTTCCCGGAGCAGCT
hBDNFq_VI_s ATCGGAACCACGATGTGACT
hBDNFq_IXc_s AACCTTGACCCTGCAGAATGGCCT
hBDNFq_IX_as1 (with I, IV_s) ATGGGGGCAGCCTTCATGCA
hBDNFq_IX_as2 (with VI_s) ACCTTGTCCTCGGATGTTTG
hBDNFq_IX_as3 (with IXc_s) GATGGTCATCACTCTTCTCACCT
mBDNFq_I_s TTGAAGCTTTGCGGATATTGCG
mBDNFq_IV_s GAAATATATAGTAAGAGTCTAGAACCTTG
mBDNFq_VI_s GCTTTGTGTGGACCCTGAGTTC
mBDNFq_IXa_s GGACTATGCTGCTGACTTGAAAGGA
mBDNFq_IX_as1 (with I, IV, VIs) AAGTTGCCTTGTCCGTGGAC
mBDNFq_IX_as2 (with IXa_s) GAGTAAACGGTTTCTAAGCAAGTG
mBDNFq_coding_s GGCCCAACGAAGAAAACCAT
mBDNFq_coding_s AGCATCACCCGGGAAGTGT
HPRT1q_s CAGTCCCAGCGTCGTGATTA
HPRT1q_as AGCAAGTCTTTCAGTCCTGTC
transgene integrity
pBACe3.6_SP6 (5'end) TATTTAGGTGACACTATAG
rp11_5'_as (5'end) GGACAACAGACCCAAGGAGA
rp11_3'_s (3'end) GTAGGGTGTCTGGGTTGGTG
pBACe3.6_T7 (3'end) TAATACGACTCACTATAGGG
transgene tandem integration
rp11_3'_s (P1) GTAGGGTGTCTGGGTTGGTG
pBACe_11326_s (P2) CGGTTACGGTTGAGTAATAAATGGATG
pBACe_11365_s (P3) GGGGCACATTTCATTACCTCTTTCTC
Table 2: PCR primers used in this study (Continued)BMC Neuroscience 2009, 10:68 http://www.biomedcentral.com/1471-2202/10/68
Page 11 of 14
(page number not for citation purposes)
used in the present study contained 39 kb longer 5' and 16
kb shorter 3' genomic regions of hBDNF gene than the
reported hBDNF-YAC construct [27]. In addition, part of
BDNF coding sequence had been replaced with EGFP
reporter gene in the hBDNF-YAC transgene [27], possibly
removing cis-elements with regulatory function. In con-
trast to the present study, hBDNF-YAC transgenic mRNA
expression was not analyzed in different brain regions and
expression of transgenic mRNAs containing exons III, V,
Vh, VII and 5'-extended exon IX was not analyzed. More
detailed comparison of hBDNF-EGFP expression in the
two hBDNF transgenic mouse models would allow nar-
rowing down genomic regions containing enhancer ele-
ments for tissue-specific expression of human BDNF. For
example, on the basis of current data it can be hypothe-
sized that a cis-element promoting heart-specific expres-
sion of hBDNF mRNA is located within the 3' terminal 16
kb of hBDNF-YAC construct (17–33 kb downstream of
the hBDNF gene; chr11:27,600,000–27,616,000; UCSC
Genome Browser, Mar 2006 Assembly). Recently, a BDNF
regulatory locus has been discovered 850 kb upstream of
the human and mouse BDNF genes that causes obesity,
cognitive impairment and hyperactivity when disrupted
[44,45]. Therefore, it is possible that in addition to regu-
latory elements included in the hBDNF-BAC of this study
and the hBDNF-YAC described before [27], others can be
found hundreds of kilobases away from the BDNF gene.
EGFP reporter gene has been successfully used to visualize
BAC-driven expression of neural genes in a number of
studies [23-25]. In the BAC construct that was used to gen-
erate transgenic mice in the present study, EGFP reporter
gene was fused C-terminally with the human BDNF cod-
ing sequence to allow detailed characterization of human
BDNF expression in the nervous system. Unfortunately,
we could not detect EGFP protein in the brain of C3 mice
neither with fluorescence microscopy nor with Western
blot analysis. This could be explained with low levels of
hBDNF-EGFP protein expressed in the C3 mouse brain as
transgenic hBDNF-EGFP mRNA levels were about tenfold
lower than these of endogenous BDNF. It is also possible
that founder mice with higher levels of BDNF-EGFP
expression died during embryonic development due to
overactivation of BDNF receptor TrkB. This hypothesis is
supported by a study showing that embryonic overexpres-
sion of BDNF from nestin promoter results in gross
abnormalities in brain architecture and perinatal death
[46]. Although the hBDNF-EGFP fusion protein can be
expressed in cultured cells in vitro [28-30], it is conceivable
that it is not translated or has poor translatability and/or
stability when expressed in transgenic mice in vivo.
Conclusion
Human genomic region covering 67 kb of the BDNF gene,
84 kb of upstream and 17 kb of downstream sequences is
able to drive tissue-specific and kainic acid-induced
expression of reporter gene in transgenic mice that largely
overlaps with BDNF gene expression and regulation in
mouse and human. This is the first study to directly show
that human BDNF gene is regulated by neural activity. The
BDNF-BAC transgenic mice are useful for studying the
transcription regulation of human BDNF gene in vivo. In
addition, these mice could be used for screening therapeu-
tic agents modulating human BDNF transcription.
Methods
Generation of transgenic mice
BAC clone (RP11-651M4) containing the human BDNF
locus [GenBank:AC087446.13] was purchased from
Chori BACPAC Resources (USA). Red®/ET® homologous
recombination in E. coli (Counter-Selection BAC Modifi-
cation Kit, Gene Bridges GmbH, Germany) was used to
delete BDNF stop codon and to insert EGFP reporter gene
with the linker sequence (CGG GAT CCA CCG GTC GCC
ACC) into the 3' end of BDNF. For sequences of primers
used for insert synthesis see Table 2. Modified BAC was
tested for the absence of rearrangements using EcoRV
restriction analysis and pulsed field gel electrophoresis.
Integrity of the hBDNF-EGFP reading frame was con-
firmed by sequencing. In order to validate the reporter
activity, BAC DNA was purified using the Large Construct
Purification Kit (Qiagen, USA) and transfected into COS-
7 cells using DEAE-dextran mediated transfection system
[47]. Five days after transfection EGFP expression and dis-
tribution in COS-7 cells was visualized using fluorescence
microscopy (Eclipse 80i upright microscope, Nikon).
hEGFP-BDNF BAC DNA was purified for microinjection
by alkaline lysis and linearized with PI-SceI enzyme (NEB,
USA). Restriction solution was separated in low-melt aga-
rose gel (Fermentas, Lithuania) using CHEF-DR II Pulsed
Field Electrophoresis System (Bio-Rad, USA). Linearized
BAC DNA was excised from the gel and purified from aga-
rose using Gelase enzyme (NEB, USA). Transgenic mice
were generated by pronuclear injection of linearized
hBDNF-EGFP-BAC into CBA × C57Bl/6 mouse pronuclei
in the Karolinska Center for Transgene Technologies
(Sweden). Founder mice carrying the BAC transgene were
identified by PCR analysis of genomic DNA. Transgene
copy number was analyzed by slot-blot hybridization of
genomic DNA with a [α-32P]dCTP-labeled probe gener-
ated with HexaLabel DNA Labeling Kit (Fermentas,
Lithuania) using pEGFP-N1 (Clontech, USA) plasmid as a
template. Genomic DNA of the C3 mouse founder line
was analyzed by PCR for the presence of 5' and 3' ends of
the linearized transgene. Tandem insertion of transgene
into the C3 line genomic DNA was analyzed by PCR with
primers pBACe_11326_s or pBACe_11365_s in combina-
tion with rp11_3'_s (see Table 2) and sequencing of the
PCR product. All animal experiments were performed inBMC Neuroscience 2009, 10:68 http://www.biomedcentral.com/1471-2202/10/68
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agreement with the local Ethical Committee of Animal
Experimentation.
Cell culture, antibodies and animal experiments
African green monkey kidney fibroblast COS-7 cells were
grown in DMEM with 10% fetal calf serum and antibiot-
ics. Primary neuronal cultures from embryonic day 18 cer-
ebral cortex were prepared as described [48]. For Western
blots and immunohistochemistry the following antibod-
ies were used: mouse anti-GFP monoclonal antibodies
(Roche Applied Science), mouse anti-GFP monoclonal
antibodies (Clontech, USA); rabbit anti-BDNF (Santa
Cruz Biotechnology, USA). For kainic acid treatment,
adult mice weighing 20–25 g were injected intraperito-
neally with 30 mg/kg of kainic acid or 1× PBS. 3 hours
later mice were decapitated, hippocampus and cortex dis-
sected, frozen on dry ice and stored at -70°C. For in situ
hybridization whole brains were embedded in Shandon
Cryomatrix™ (Thermo Fisher Scientific, USA). Four kainic
acid-treated C3 mice and two control mice were used for
quantitative RT-PCR analysis of total hBDNF-EGFP
mRNA expression in the cerebral cortex and hippocam-
pus. Total hBDNF-EGFP mRNA was induced 2,5–6 fold in
the hippocampus of kainic acid-treated C3 mice and the
mouse displaying highest induction of hBDNF-EGFP and
mBDNF mRNA was analyzed further with RT-PCR for
expression of exon-specific transcripts. Five kainic acid-
treated C3 mice and two control mice were used for in situ
hybridization analysis and the mouse showing highest
induction of hBDNF-EGFP and mBDNF mRNA was fur-
ther analyzed in more detail.
RT-PCR
Total RNA was isolated from mouse and human tissues
using TRI reagent (Ambion, USA). All experiments with
human tissues were approved by the local Ethical Com-
mittee for Medical Research. Two mice from each trans-
genic line were analyzed for tissue-specific expression of
hBDNF-EGFP mRNA in brain regions and non-neural tis-
sues and they showed identical transgene expression pat-
tern. RNA was treated with DNase (DNA-free, Ambion,
USA) following manufacturer's instructions and five
micrograms of total RNA was used for cDNA synthesis
with oligo-dT primer (Microsynth, Switzerland) and
SuperScript III reverse transcriptase (Invitrogen, USA).
PCR amplification was carried out with HotFire DNA
polymerase (Solis Biodyne, Estonia) according to the
manufacturer's instructions. Quantitative real-time PCR
was performed on a LightCycler 2.0 instrument (Roche
Applied Science) using qPCR Core kit for SYBR® Green I
No ROX (Eurogentec, Belgium). Melting curve analysis
was carried out at the end of cycling to confirm amplifica-
tion of a single PCR product. All qPCR reactions were per-
formed in triplicate and normalized to hypoxanthin
phosphoribosyltransferase 1 (HPRT1) mRNA levels.
Ribonuclease protection assay
For cRNA synthesis 624 bp BDNF-EGFP fragment con-
taining 452 bp of BDNF, 21 bp linker sequence and 151
bp of EGFP sequence was amplified with PCR from mod-
ified BAC clone RP11-651M4 and cloned into pBluescript
SK+ vector (Stratagene, USA). [α-32P]UTP-labeled cRNA
probe was in vitro transcribed from linearized plasmid
template using MAXIscript Kit and T3 polymerase
(Ambion, USA). 10 μg of total RNA and 2.5 ×105 CPM of
radiolabeled probe were used for RPA hybridization and
the assay was performed with the RPA III Kit from
Ambion as suggested by the manufacturer. The protected
fragments were separated in 4% acrylamid-urea gel and
detected autoradiographically using BioRad Molecular
Imager FX.
In situ hybridization
cRNA probe complementary to the coding region was
used to mouse BDNF mRNA and probe complementary
to EGFP was used to detect hBDNF mRNA. Probes were
synthesized from DNA fragments subcloned into pCR4-
TOPO vector (Invitrogen, USA). [α-35S]UTP-labeled
probes were generated with MAXIScript In Vitro Transcrip-
tion Kit (Ambion, USA) using linearized DNA template
and T3 or T7 RNA polymerase. 16 μm sections of fresh-
frozen C3 mouse brain were processed according to the
protocol described in [13]. Slides were exposed to either
BioMax MR X-ray film for one week or NTB-2 photoemul-
sion for 2 months, developed with D19 developer and
fixed with a general-purpose fixer (all from Eastman
Kodak, USA). Slides exposed to NTB-2 were counter-
stained with hematoxylin (Vector Laboratories Inc., USA).
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